Acacia Research Corporation — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; interim financial statements are unaudited. Acacia’s subsidiaries acquire, license and enforce patent rights, with revenue largely dependent on licensing agreements and enforcement outcomes.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $34.2 million | $12.6 million; up 172% |
| Operating loss | $13.6 million | $26.1 million loss |
| Net loss attributable to Acacia | $13.1 million | $24.4 million loss |
| Loss per share, basic and diluted | $0.27 | $0.51 |
| Operating cash flow | $15.8 million used | $20.4 million used |
| Cash and cash equivalents | $101.5 million | $134.5 million at Dec. 31, 2014 |
| Short-term investments | $53.3 million | $58.6 million at Dec. 31, 2014 |
| Debt | No long-term debt reported |
Operating loss was approximately 39.8% of revenue, compared with approximately 207% in Q1 2014. Cash, cash equivalents and investments excluding restricted cash totaled $154.8 million at quarter-end; including $10.7 million of restricted cash, the total was $165.6 million. Working capital, including restricted cash, was $169.0 million. The company paid $6.4 million in dividends and declared a quarterly dividend of $0.125 per share, payable May 29, 2015.
Material changes and management commentary
- Revenue growth reflected a higher average revenue per agreement: $1.49 million versus $0.63 million, while agreements increased to 23 from 20. Two licensing programs generated initial revenue.
- Higher revenue was partly offset by inventor royalties and contingent legal fees, which together rose $11.6 million. Management attributed higher royalty rates primarily to lower cost recoveries for portfolios generating Q1 revenue.
- Patent amortization declined 10% to $13.0 million, mainly because Q1 2014 included a $2.6 million portfolio impairment-related charge. Marketing, general and administrative expense declined 10% to $10.6 million, including lower noncash stock compensation.
- Trailing 12-month revenue was $152.5 million, 17% above the comparable figure a year earlier. Management cautioned that quarterly revenue is uneven and does not manage for smooth period-to-period growth.
- Management said available cash, investments and anticipated operating cash flows should meet cash requirements through at least May 2016. No specific revenue or earnings guidance was provided.
Risks, contingencies and unusual items
- Revenue and receivables are concentrated: two licensees generated 58% and 15% of Q1 revenue and represented approximately 66% and 17% of quarter-end receivables, respectively.
- Operating cash flow remained negative. Cash receipts from licensees rose, but operating outflows also increased; patent investments totaled $16.9 million in Q1.
- A $10.7 million cash deposit is restricted to secure a guarantee supporting enforcement of a German patent injunction. The guarantee may be called if the ruling is successfully appealed or amended, and is automatically extended unless extinguished under German law.
- A federal court deemed a lawsuit initiated in 2013 exceptional. Acacia accrued $426,000 for the matter and said its subsidiary was challenging the requested amounts, including through an appeal.
- Patent enforcement entails litigation-cost, adverse-ruling, sanctions, fee-shifting and legislative risks. A separate California insurance-fraud case was dismissed with prejudice in Acacia’s favor in March 2015.
- Tax valuation allowances were recorded for current-period tax assets; the Q1 2015 tax provision was $170,000. The filing also reports approximately $2.1 million of unrecognized tax benefits.
Important facts for investors to verify
- Whether the elevated revenue level and licensee collections continue, given the company’s stated revenue volatility and customer concentration.
- Collection timing for the $30.0 million of receivables and payment timing for $19.1 million of royalties and contingent legal fees payable.
- Developments in the German injunction and guarantee, including any appeal, settlement or release of restricted cash.
- Further legal expenses, sanctions or appeal outcomes related to the exceptional-lawsuit finding, and spending on patent acquisitions and enforcement.
- The sustainability of quarterly dividends relative to operating cash use, patent investment requirements and available unrestricted liquidity.